Immunogenicity of SARS-CoV-2 messenger RNAvaccines in patients with cancer
https://reader.elsevier.com/reader/s...20210701133648
SUMMARYPatientswithcancerexperienceahigherburdenof SARS-CoV-2infection,diseaseseverity,complications,andmortal ity, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general popula-tion; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, weassessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first andsecond dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europefrom January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vac-cine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were signifi-cantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the6monthsbeforevaccinationdevelopedantibodyrespon se.Antibodytiterswerehighestforclinicalsurveillanc eor endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.
Threaded Mode